Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Onconetix ( (ONCO) ) has provided an announcement.
On March 28, 2025, James Sapirstein resigned as Executive Chairman and a member of the Board of Directors of Onconetix, Inc. Subsequently, on April 2, 2025, the company appointed Karina Fedasz as Interim Chief Executive Officer. Fedasz brings over two decades of experience in capital raising, business modeling, and mergers and acquisitions, having previously worked with companies like Evofem Biosciences and IDW Media Holdings. Her appointment is expected to leverage her dynamic, growth-oriented approach to enhance Onconetix’s strategic positioning.
More about Onconetix
YTD Price Performance: -87.85%
Average Trading Volume: 6,923,610
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.1M
See more data about ONCO stock on TipRanks’ Stock Analysis page.